Access to Risk Finance is part of the „Industrial Leadership“ pillar under Horizon 2020 and helps companies and other types of organisation engaged in research and innovation (R&I) to gain easier access, via financial instruments, to loans, guarantees, counter-guarantees and hybrid, mezzanine and equity finance.
The European Investment Bank (EIB) and the European Investment Fund (EIF) play an important role including conducting calls for expressions of interest for selecting the financial intermediaries, such as banks, other lenders and risk-capital funds, that make the actual loans to or investments in SMEs and midcaps.
Below a list of the most important financial instruments:
|Debt Finance for
|Science||Loan||R&I Infrastructures Universities Research and Technology Organisations||25-300|
|Loan||Entities in countries having limited support under InnovFin||25-300|
|MidCap Guarantee||Guarantee to Financial Itermediaries||Large Midcaps||0-50|
|Corporate Research Equity Pilot||Loan||Large Midcaps||100-150|
|Thematic Finance for R&I|
|Energy Demo Projects (EDP)||Loan||Commerical-scale Industrial Demonstration Projects||7.5-25|
|Infectiouis Diseases (ID)||Loan||SMEs, Midcaps, Special Project Vehicles, Research Instiutions and Other Legal Entities||7.5-75|
|SMEs & Small Midcaps Service|
|SME Guarantee (SMEG)||Guarantees to Financial Intermediaires||R&I Driven SMEs and Midcaps||0.025-7.5|
|Equity||Equity Financing through Financial Intermediaires||SMEs, Small Medcaps|
|EIC Horizon Prizes|
'Midcaps' are deemed to be enterprises comprising 250 to 3000 employees (in full-time equivalents). They are divided into 'small midcaps' of between 250 and 499 employees, and 'medium and large midcaps' of from 500 to 3000 employees.
All serviced are delivered through financial intermediaries (except InnovFin Science, InnovFin Energy Demo Project and InnovFin Infectious Diseases).
For information about the next Research and Innovation Framework Programme FP9 (2021-2027), please visit our Horizon Europe webpage.